Citigroup Inc Protalix Bio Therapeutics, Inc. Transaction History

Citigroup Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$1.1 - $1.32 $12,566 - $15,079	-11,424 Reduced 89.73%	1,307 $1,000
Q1 2024 May 10, 2024	BUY	$1.22 - $1.82 $1,439 - $2,147	1,180 Added 10.22%	12,731 $16,000
Q4 2023 Feb 09, 2024	BUY	$1.34 - $1.85 $12,941 - $17,867	9,658 Added 510.2%	11,551 $20,000
Q3 2023 Nov 09, 2023	SELL	$1.49 - $2.02 $24,659 - $33,431	-16,550 Reduced 89.74%	1,893 $3,000
Q2 2023 Aug 10, 2023	BUY	$2.0 - $3.36 $36,886 - $61,968	18,443 New	18,443 $36,000
Q2 2022 Aug 10, 2022	SELL	$1.02 - $1.56 $306 - $468	-300 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$0.81 - $1.17 $243 - $351	300 New	300 $0

3.58M

61.1K

36.2K

Ticker PLX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,753,400
Market Cap $87.1M
Description
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.